Vical Completes Enrollment And Reports Positive Interim Data In CMV Vaccine Phase 2 Trial
Nov 21st 2008Drug InformationTransplants
Vical Incorporated (Nasdaq: VICL) announced that the company has completed enrollment of subjects in a Phase 2 trial of its therapeutic DNA vaccine designed to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. An interim analysis of immunogenicity data for the first 33 transplant recipients in the recipient-only arm of the study showed significant (p
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
